Last reviewed · How we verify

Butanedioic Acid (SUCCINIC ACID)

FDA-approved active Small molecule Under review Quality 20/100

Butanedioic Acid (generic name: SUCCINIC ACID) is a Vitamin C [EPC] drug. It is currently FDA-approved for Iron deficiency anemia.

Butanedioic acid, also known as succinic acid, is a small molecule. It is being studied in clinical trials for various conditions, including ischemic stroke, hypertension, and neuromyelitis optica spectrum disorder.

At a glance

Generic nameSUCCINIC ACID
Drug classVitamin C [EPC]
TargetEgl nine homolog 1
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Butanedioic Acid

What is Butanedioic Acid?

Butanedioic Acid (SUCCINIC ACID) is a Vitamin C [EPC] drug, indicated for Iron deficiency anemia.

What is Butanedioic Acid used for?

Butanedioic Acid is indicated for Iron deficiency anemia.

What is the generic name of Butanedioic Acid?

SUCCINIC ACID is the generic (nonproprietary) name of Butanedioic Acid.

What drug class is Butanedioic Acid in?

Butanedioic Acid belongs to the Vitamin C [EPC] class. See all Vitamin C [EPC] drugs at /class/vitamin-c-epc.

What development phase is Butanedioic Acid in?

Butanedioic Acid is FDA-approved (marketed).

What does Butanedioic Acid target?

Butanedioic Acid targets Egl nine homolog 1 and is a Vitamin C [EPC].

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing